Literature DB >> 36162877

DENTAL AEROSOLS SHOULD NOT BE IGNORED DURING THE COVID-19 PANDEMIC UNTIL PROVEN OTHERWISE.

Poramate Pitak-Arnnop, Prim Auychai, Andreas Neff.   

Abstract

ARTICLE TITLE AND BIBLIOGRAPHIC INFORMATION: Meethil AP, Saraswat S, Chaudhary PP, Dabdoub SM, Kumar PS. Sources of SARS-CoV-2 and other microorganisms in dental aerosols. J Dent Res 2021;100(8);817-23. doi: 10.1177/00,220,345,211,015,948. SOURCE OF FUNDING: The authors reported that no external funding sources directly supported this study. TYPE OF STUDY/
DESIGN: Experimental research.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; Dental aerosol; SARS-CoV-2

Mesh:

Year:  2022        PMID: 36162877      PMCID: PMC9080706          DOI: 10.1016/j.jebdp.2022.101745

Source DB:  PubMed          Journal:  J Evid Based Dent Pract        ISSN: 1532-3382            Impact factor:   5.100


SORT, Strength of Recommendation Taxonomy. See article 101482 for complete details regarding SORT and LEVEL OF EVIDENCE grading system.

SUMMARY

Subject Selection

This was an experimental research in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for human observational investigations. Meethil et al. enrolled a sample of 28 dental patients and 5 dental personnel between May 4, and July 10, 2020 at the College of Dentistry of the Ohio State University. Inclusion criteria were not mentioned. The subjects for dental treatments were excluded, if they were <18 years, currently pregnant, previously treated with antibiotics, or self-reported about HIV infection or COVID-19, or COVID-19–like symptoms since January 2020 (ie all symptomatic cases were excluded). The investigators calculated the sample size based on in vitro and clinical non-SARS-CoV-2-related studies.

Key Exposure/Study Factor

The aerosol-generating dental procedures (AGDPs) were performed under high-power suctioning by 5 dentists and dental assistants wearing N95 masks in 2 enclosed operatories measuring 10.5 × 10 × 12 feet, with 6-exchange/min ventilation. All except 5 scaling patients (82.1%) rinsed 1% H2O2 30 mL for 1 minute before treatment began. The predictor variables included 1) timing in relation to dental treatments (before vs after [30 minutes after treatment end]), 2) location of specimen collecting (operator [dentist's face shield] vs assistant [assistant's face shield] vs patient [patient's chest] vs environment [an area of 6 feet from the site of operation]), 3) source of specimen (saliva vs aerosol), 4) type of AGDPs (dental implant placement vs restorative procedures with high-speed handpieces vs ultrasonic scaling; there was no control group without an AGDP), and 5) type of microorganisms (SARS-CoV-2 vs other [over 1250 microorganisms other than SARS-CoV-2; the sizes of these microorganisms were not reported]).

Main Outcome Measure

The main outcome variable was the frequency of identifiable microorganisms, which was measured by microbiologic-genetic techniques for microbial DNA sequences, and an RNA extraction-free dualplexed reverse transcriptase quantitative polymerase chain reaction (qRT-PCR) for SARS-CoV-2 detection (SalivaDirect version 5).

Main Results

There were statistical significances between postoperative salivary and aerosol microbiota, regardless of type of AGDPs and location of sample collecting (P < .001, Dunn method for joint ranking of Bray-Curtis dissimilarity distances). Vulcaniibacteria was identifiable in 70% of microbial abundance. The aerosolized microbial abundance was 8.3-10 times more than saliva bacteria, which were found in 8 (or 28.6%) patients [5 of those did not rinse H2O2]. However, the source of 0%-90% of the microbiota (mean, 20%) was unknown. The patient's chest was the most frequent site of germ deposition (P < .05, chi-square test), despite in 8 patients only. On the contrary, SARS-CoV-2 was detected in saliva of 19 participants (viral load, 27-912 copies/mL). No aerosol with SARS-CoV-2 in any location was found.

Conclusions

The investigators concluded that with appropriate infection control measures, that is, preoperative mouth rinses and intraoral high-volume suction, dental treatment in asymptomatic patients does not decrease the risk of SARS-CoV-2 transmission. Standard infection control is sufficient to protect personnel and patients from exposure to potential pathogens.

COMMENTARY AND ANALYSIS

The microbial aerosol is a stable colloidal system of microorganisms floating in the air in the state of a single cell suspension or fused with dry solid or liquid particles. Viral aerosols have a small size and have Brownian motion, causing a long-time suspension, far-distance transmission, and access to the lower respiratory tract. Dental environment are in closed spaces, and many AGDPs intensively generate aerosols compared to normal-life activities. Since the risk of SARS-CoV-2 infection is cumulative, directly proportional to the duration of exposure (apart from the viral density), repeated inhalation of several particles, although containing smaller viral doses) can inevitably lead to an infection. Theoretically, aerosol particles are dry very quickly: milliseconds to seconds. Enveloped RNA viruses, for example, influenza, and coronaviruses, may be unstable in dried aerosol nuclei for extended periods, limiting the viral ability to transmit. The SARS-CoV-2, conversely, remains viable in aerosols for 3 hours with a reduction in infectious titer from 103.5 to 102.7 mean (or 50%) tissue culture infectious dose (TCID50)/L air at 21-23°C and 65% relative humidity.  A Florida study demonstrated “viable” SARS-CoV-2 isolated from air samples collected 2 to 4.8 m (6.6-15.7 ft.) away from the patients in the absence of AGDPs. For aerosol-based transmission, measures such as physical distancing by 6 feet would not be helpful in an indoor setting, provide a false sense of security, and lead to exposures and outbreaks. Furthermore, AGDPs increase humidity in dental environments. Airflow dispersed by human activities, ventilation, and high-power suctioning could also cause resuspension of the aerosols that are already deposited on the surfaces. Recently, we found SARS-CoV-2 distribution in an operating theater up to 3 m during midfacial fracture repair under general anesthesia. Hence, SARS-CoV-2 transmission from asymptomatic or mildly symptomatic patients should not be underestimated, especially in areas with an incidence of ≥150 new cases per 100,000 population per week. Meethil et al. enrolled a cohort of 28 dental patients with unknown inclusion criteria and appeared unrepresentative to the real-world statistics, that is, selection bias is possible. Moreover, they detected a viral load of 27-912 copies/mL, although SalivaDirect can actually detect viral loads as low as 600012,000 copies/mL. Compared to reverse transcription-polymerase chain reaction (qRT-PCR), SalivaDirect had false-positive rates of 0.03%-0.05% (n = 3760), suggesting the missing of ≥2 COVID-19 patients in the Meethil et al.’s study. A meta-analysis showed that salivary SARS-CoV-2 testing may be less sensitive (up to 16.6 times) than qRT-PCR. SalivaDirect provides significantly lower detect rates: 61.9%-96.4%. This could be a result of accidental collection of sputum and/or remnants from food/drinks, or even brushing teeth prior to saliva collection, which can interfere sample processing or inhibit PCR. , The discrepancies between salivary testing vs standard RT-PCR, amid cheaper, tend to decrease in asymptomatic or mildly symptomatic patients, and can be used “only” for screening in communities. , Given sample size calculation for differences in measurements among 3 unpaired groups (ultrasonic scaling vs drilling vs implant placement) at α = 0.05 and power of 80%, the overall effect size (calculated from the salivary viral load: 175.73 ± 235.08 vs 44.43 ± 13.74 vs 29.85 ± 46.49, respectively) will be 7.21, and ≥29 subjects are required in each study arm (i.e., total sample size ≥87). The low sample size in Meethil et al.’s study may explain the insignificance among AGDP types (i.e., the results could not escape from the β-error). Gargling with 1%-3% H2O2 in the mouth and throat for 1 minute 1-3 times a day (for up to 6 months) has proven effective against SARS-CoV-2. The antiseptic action via oxidizing and mechanical removal is intensified by the induction of the innate antiviral inflammatory response by overexpression of Toll-like receptor 3 (TLR3). In conclusion, several factors in the Meethil et al.’s study, for example, high probability of selection bias and non-representative samples, inappropriate use of salivary SARS-CoV-2 testing as standard in the research setting, improper analysis of dental aerosols, and the high risk of β-errors (i.e., false-negative errors) due to the low sample size, could altogether compromise the scientific integrity. This paper's findings may cause great confusion in dental communities during the COVID-19 pandemic, and thereby, should be interpreted cautiously. We refer interested readers to up-to-date dental management during the COVID-19 pandemic by Hegde et al., and our meta-narrative review of oral-maxillofacial manifestations in COVID-19 patients.
SORT SCORE

ABCN/A

SORT, Strength of Recommendation Taxonomy.

LEVEL OF EVIDENCE
123

See article 101482 for complete details regarding SORT and LEVEL OF EVIDENCE grading system.

  12 in total

1.  Evidence-based oral and maxillofacial surgery: some pitfalls and limitations.

Authors:  Poramate Pitak-Arnnop; Alexander Hemprich; Niels Christian Pausch
Journal:  J Oral Maxillofac Surg       Date:  2010-11-02       Impact factor: 1.895

Review 2.  A German AWMF's S2e/realist synthesis and meta-narrative snapshot of craniomaxillofacial manifestations in COVID-19 patients: Rapid living update on 1 January 2021.

Authors:  Poramate Pitak-Arnnop; Jean-Paul Meningaud; Nattapong Sirintawat; Keskanya Subbalekha; Prim Auychai; Anak Iamaroon; Pornchai O-Charoenrat; Surajit Suntorntham; Robert Messer-Peti; Andreas Neff
Journal:  J Stomatol Oral Maxillofac Surg       Date:  2021-01-30       Impact factor: 1.569

3.  Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients.

Authors:  John A Lednicky; Michael Lauzardo; Z Hugh Fan; Antarpreet Jutla; Trevor B Tilly; Mayank Gangwar; Moiz Usmani; Sripriya Nannu Shankar; Karim Mohamed; Arantza Eiguren-Fernandez; Caroline J Stephenson; Md Mahbubul Alam; Maha A Elbadry; Julia C Loeb; Kuttichantran Subramaniam; Thomas B Waltzek; Kartikeya Cherabuddi; J Glenn Morris; Chang-Yu Wu
Journal:  Int J Infect Dis       Date:  2020-09-16       Impact factor: 3.623

4.  Might hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection?

Authors:  Arturo A Caruso; Antonio Del Prete; Antonio I Lazzarino; Roberto Capaldi; Lucia Grumetto
Journal:  Infect Control Hosp Epidemiol       Date:  2020-04-22       Impact factor: 3.254

5.  The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis.

Authors:  Mayara Lisboa Bastos; Sara Perlman-Arrow; Dick Menzies; Jonathon R Campbell
Journal:  Ann Intern Med       Date:  2021-01-12       Impact factor: 25.391

6.  SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg.

Authors:  Paul Wilmes; Jacques Zimmer; Jasmin Schulz; Frank Glod; Lisa Veiber; Laurent Mombaerts; Bruno Rodrigues; Atte Aalto; Jessica Pastore; Chantal J Snoeck; Markus Ollert; Guy Fagherazzi; Joël Mossong; Jorge Goncalves; Alexander Skupin; Ulf Nehrbass
Journal:  Lancet Reg Health Eur       Date:  2021-02-27

Review 7.  SARS-CoV-2 aerosol and droplets: an overview.

Authors:  Udaykumar Ranga
Journal:  Virusdisease       Date:  2021-04-22

Review 8.  Aerosol Transmission of Coronavirus and Influenza Virus of Animal Origin.

Authors:  Jing Lv; Jing Gao; Bo Wu; Meiling Yao; Yudong Yang; Tongjie Chai; Ning Li
Journal:  Front Vet Sci       Date:  2021-04-13

9.  SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity.

Authors:  Chantal B F Vogels; Anne E Watkins; Christina A Harden; Doug E Brackney; Jared Shafer; Jianhui Wang; César Caraballo; Chaney C Kalinich; Isabel M Ott; Joseph R Fauver; Eriko Kudo; Peiwen Lu; Arvind Venkataraman; Maria Tokuyama; Adam J Moore; M Catherine Muenker; Arnau Casanovas-Massana; John Fournier; Santos Bermejo; Melissa Campbell; Rupak Datta; Allison Nelson; Charles S Dela Cruz; Albert I Ko; Akiko Iwasaki; Harlan M Krumholz; J D Matheus; Pei Hui; Chen Liu; Shelli F Farhadian; Robby Sikka; Anne L Wyllie; Nathan D Grubaugh
Journal:  Med (N Y)       Date:  2020-12-26

10.  Inanimate surface contamination of SARS-CoV-2 during midfacial fracture repair in asymptomatic COVID-19 patients.

Authors:  Poramate Pitak-Arnnop; Nattapong Sirintawat; Chatpong Tangmanee; Passanesh Sukphopetch; Jean-Paul Meningaud; Andreas Neff
Journal:  J Stomatol Oral Maxillofac Surg       Date:  2022-01-19       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.